Clearpath Health Network — Intelligence Profile

Health Score

3/10

Confidence high

The account data is consistent, multi-sourced, and spans a clear timeline; CRM notes, usage signals, support tickets, and email history all corroborate the same narrative of a compliance-blocked, low-adoption account with a passive champion, leaving little ambiguity in the assessment.

Account Narrative

Clearpath Health Network is significantly underutilizing the platform nearly five months post-implementation, with only 2 of 22 seats actively used and just 3 of 16 features engaged. The primary blocker is a stalled BAA amendment process that has prevented IT from approving broader clinical staff provisioning — a bureaucratic obstacle that has persisted for over three months with no resolution in sight. With renewal approaching in January 2025 and no demonstrated value across the majority of purchased seats, this account faces meaningful churn risk if the IT/compliance logjam is not broken soon.

Key Signals

−

Only 2 of 22 provisioned seats are active in the last 30 days (9% seat utilization) usage

−

Only 3 of 16 features used; workflow automation, analytics dashboards, and integrations entirely untouched usage

−

BAA amendment has been pending IT/legal approval for 3+ months with no resolution, blocking full team provisioning crm

−

Dr. Foster and team show no urgency to resolve adoption blockers or escalate internally email

＋

CSM proactively offered to loop in legal and IT contacts to accelerate BAA process email

∼

Support ticket for role-based access configuration suggests at least some intent to scale user setup when unblocked support

∼

Initial onboarding was completed and two training sessions were delivered, establishing a baseline foothold crm

Expansion Opportunities

Full seat activation across all 22 provisioned users once BAA is resolved medium

The role-based access support ticket and department head involvement suggest structural readiness to scale; the blocker is compliance, not interest

Adoption of workflow automation and analytics dashboards for clinical ops use cases low

Dr. Foster's role in Clinical Ops aligns directly with these unused features; if provisioning is unblocked, there is a natural expansion path into higher-value feature tiers

Risk Factors

Renewal at risk due to near-zero demonstrated ROI — customer has not activated 91% of purchased seats high

2 of 22 active seats, 3 of 16 features used, declining login trend; renewal date is 2025-01-10 leaving limited time to reverse trajectory

BAA amendment stalemate could persist indefinitely without vendor-side intervention high

Blocker first noted in February 2024 implementation close; still unresolved as of May 2024 QBR; IT estimated 6-8 weeks in late February but no resolution confirmed

Champion (Dr. Foster) is passive and not actively advocating for the product internally high

Dr. Foster expressed no urgency in April email, deferred all action to IT clearance, and has not escalated the BAA issue despite its impact on team adoption

No executive sponsor or internal champion identified beyond Dr. Foster, limiting leverage to drive resolution medium

All CRM and email interactions are exclusively with Dr. Foster; no VP, CIO, or C-suite contact documented

Continued inaction through summer could leave insufficient runway to demonstrate value before the January renewal medium

Even if BAA resolves in June, onboarding 20 additional clinical staff and achieving meaningful adoption by January 2025 is a tight timeline

Next Actions

CSM this week

Escalate BAA amendment resolution: CSM should request a tri-party call including Clearpath's IT contact Kyle Marsh, Dr. Foster, and your company's legal/compliance team this week — offer to provide data residency and encryption documentation proactively to remove remaining open questions

Sales this week

Identify and engage an executive sponsor above Dr. Foster (e.g., CIO or VP of Operations) to create internal urgency around the BAA resolution and platform adoption

Leadership this month

Conduct an internal account review to assess whether this account is at churn risk and determine if a leadership-to-leadership outreach is warranted to signal the partnership's strategic importance

CSM this month

Develop a time-boxed adoption recovery plan: once BAA is resolved, pre-schedule phased onboarding sessions for clinical staff with clear 90-day milestones tied to renewal conversation

CSM monitor

Monitor IT/BAA status weekly and set a hard internal deadline — if unresolved by July 2024, trigger executive escalation protocol